Advanced search
1 file | 496.79 KB

Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?

(2018) MOLECULAR IMMUNOLOGY. 101. p.521-526
Author
Organization
Abstract
Multiple myeloma (MM) is a progressive monoclonal B cell malignancy, for which survival and progression largely relies on the crosstalk of tumor cells with the bone marrow (BM) microenvironment, inducing immune escape, angiogenesis, bone destruction and drug resistance. Despite great therapeutic advances, most of the MM patients still relapse and remain incurable. Over the past years, immunotherapy has emerged as a new field in cancer therapy. Here, the immune cells of the patients themselves are activated to target the tumor cells. In MM, several effector cells of the immune system are present in the BM microenvironment; unfortunately, they are mostly all functionally impaired. In this review, we focus on the role of innate-like T cells in MM, particularly CD1d- and MR1- restricted T cells such as respectively invariant natural killer T (iNKT) cells and mucosal associated invariant T (MATT) cells. These cells have the capacity upon activation to rapidly release copious amounts of cytokines affecting a wide range of innate and adaptive immune responses, and could therefore play a key protective role in anti-tumor immunity. We describe recent observations with regard to functional exhaustion of iNKT and MALT cells in MM pathology and discuss the potential application of checkpoint inhibition as an attractive target for prolonged activation of these immunomodulatory T cells in the treatment of MM.
Keywords
INVARIANT NKT CELLS, MUCOSAL-ASSOCIATED INVARIANT, BONE-MARROW, THERAPEUTIC TARGET, MAIT CELLS, CANCER, IMMUNOTHERAPY, RESPONSES, BLOCKADE, BIOLOGY, iNKT cells, MAIT cells, Multiple myeloma, Checkpoint inhibition

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 496.79 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Venken, Koen, Mérédis Favreau, Djoere Gaublomme, Eline Menu, Karin Vanderkerken, and Dirk Elewaut. 2018. “Checkpoint Inhibition in the Treatment of Multiple Myeloma: A Way to Boost Innate-like T Cell Anti-tumor Function?” Molecular Immunology 101: 521–526.
APA
Venken, K., Favreau, M., Gaublomme, D., Menu, E., Vanderkerken, K., & Elewaut, D. (2018). Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function? MOLECULAR IMMUNOLOGY, 101, 521–526.
Vancouver
1.
Venken K, Favreau M, Gaublomme D, Menu E, Vanderkerken K, Elewaut D. Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function? MOLECULAR IMMUNOLOGY. Oxford: Pergamon-elsevier Science Ltd; 2018;101:521–6.
MLA
Venken, Koen, Mérédis Favreau, Djoere Gaublomme, et al. “Checkpoint Inhibition in the Treatment of Multiple Myeloma: A Way to Boost Innate-like T Cell Anti-tumor Function?” MOLECULAR IMMUNOLOGY 101 (2018): 521–526. Print.
@article{8583107,
  abstract     = {Multiple myeloma (MM) is a progressive monoclonal B cell malignancy, for which survival and progression largely relies on the crosstalk of tumor cells with the bone marrow (BM) microenvironment, inducing immune escape, angiogenesis, bone destruction and drug resistance. Despite great therapeutic advances, most of the MM patients still relapse and remain incurable. Over the past years, immunotherapy has emerged as a new field in cancer therapy. Here, the immune cells of the patients themselves are activated to target the tumor cells. In MM, several effector cells of the immune system are present in the BM microenvironment; unfortunately, they are mostly all functionally impaired. In this review, we focus on the role of innate-like T cells in MM, particularly CD1d- and MR1- restricted T cells such as respectively invariant natural killer T (iNKT) cells and mucosal associated invariant T (MATT) cells. These cells have the capacity upon activation to rapidly release copious amounts of cytokines affecting a wide range of innate and adaptive immune responses, and could therefore play a key protective role in anti-tumor immunity. We describe recent observations with regard to functional exhaustion of iNKT and MALT cells in MM pathology and discuss the potential application of checkpoint inhibition as an attractive target for prolonged activation of these immunomodulatory T cells in the treatment of MM.},
  author       = {Venken, Koen and Favreau, M{\'e}r{\'e}dis and Gaublomme, Djoere and Menu, Eline and Vanderkerken, Karin and Elewaut, Dirk},
  issn         = {0161-5890},
  journal      = {MOLECULAR IMMUNOLOGY},
  language     = {eng},
  pages        = {521--526},
  publisher    = {Pergamon-elsevier Science Ltd},
  title        = {Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?},
  url          = {http://dx.doi.org/10.1016/j.molimm.2018.08.019},
  volume       = {101},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: